This clinical trial is focused on studying the effects of a medication called Rituximab in patients with Rheumatoid Arthritis, a condition that causes pain and swelling in the joints. The study aims to compare a lower dose of 200 mg of Rituximab given every six months to the standard higher dose of 1 gram, to see if the lower dose is just as effective in managing the disease.
Participants in the study will receive Rituximab through an infusion, which means the medication is delivered directly into the bloodstream. The study will last for about a year, during which the participants’ disease activity will be monitored at the start, at six months, and at the end of the study. This will help determine if the lower dose of Rituximab can maintain the same level of disease control as the higher dose.
The goal of the study is to find out if using a smaller amount of Rituximab can still effectively manage Rheumatoid Arthritis without increasing the disease activity. This could potentially lead to fewer side effects and a more convenient treatment option for patients. The study will also track any changes in the participants’ health and any side effects they may experience during the trial period.
France 